Your browser doesn't support javascript.
loading
CD44-negative parietal-epithelial cell staining in minimal change disease: association with clinical features, response to corticosteroids and kidney outcome.
Roca, Neus; Jatem, Elias; Abo, Anabel; Santacana, Maria; Cruz, Alejandro; Madrid, Álvaro; Fraga, Gloria; Martin, Marisa; Gonzalez, Jorge; Martinez, Cristina; Balius, Anna; Segarra, Alfons.
Afiliación
  • Roca N; Servicio Nefrologia Pediátrica, Hospital Universitari de Vic, Universitat de Vic, Barcelona, Spain.
  • Jatem E; Servicio de Nefrologia, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
  • Abo A; Institut de Recerca Biomèdica Dr Pifarré, Lleida, Spain.
  • Santacana M; Institut de Recerca Biomèdica Dr Pifarré, Lleida, Spain.
  • Cruz A; Servicio de Nefrologia Pediátrica, Hospital Universitario Vall d'Hebrón, Barcelona, Spain.
  • Madrid Á; Servicio de Nefrologia Pediátrica, Hospital Sant Joan de Dèu Barcelona, Barcelona, Spain.
  • Fraga G; Servicio de Nefrologia Pediátrica, Hospital Universitario Vall d'Hebrón, Barcelona, Spain.
  • Martin M; Servicio de Nefrologia, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
  • Gonzalez J; Servicio de Nefrologia, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
  • Martinez C; Institut de Recerca Biomèdica Dr Pifarré, Lleida, Spain.
  • Balius A; Servicio de Nefrologia, Fundació Althaia de Manresa, Barcelona, Spain.
  • Segarra A; Servicio de Nefrologia, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
Clin Kidney J ; 15(3): 545-552, 2022 Mar.
Article en En | MEDLINE | ID: mdl-35211308
ABSTRACT

BACKGROUND:

Activation of parietal-epithelial cells (PECs) with neo-expression of CD44 has been found to play a relevant role in the development of focal and segmental glomerulosclerosis (FSGS). The aim of this study was to analyse whether the expression of CD44 by PECs in biopsies of minimal change disease (MCD) is associated with the response to corticosteroids, with kidney outcomes and/or can be considered an early sign of FSGS.

METHODS:

This multicentric, retrospective study included paediatric and adult patients with MCD. Demographic, clinical and biochemical data were recorded, and biopsies were stained with anti-CD44 antibodies. The association between PECs, CD44 expression and the response to corticosteroids, and kidney outcomes were analysed using logistic, Kaplan-Meier and Cox regression analyses.

RESULTS:

A total of 54 patients were included 35 (65%) <18 years and 19 (35%) adults. Mean follow-up was 68.3 ± 37.9 months. A total of 19/54 patients (35.2%) showed CD44-positive staining. CD44-positive patients were younger (14.5 ± 5 versus 21.5 ± 13, P = 0.006), and showed a higher incidence of steroid-resistance [11/19 (57.8%) versus 7/35 (20%), P = 0.021; odds ratio 5.5 (95% confidence interval 1.6-18), P = 0.007] and chronic kidney disease [9/19 (47.3%) versus 6/35 (17.1%), P = 0.021; relative risk 3.01 (95% confidence interval 1.07-8.5), P = 0.037]. Follow-up re-biopsies of native kidneys (n = 18), identified FSGS lesions in 10/12 (83.3%) of first-biopsy CD44-positive patients versus 1/6 (16.7%) of first-biopsy CD44-negative patients (P = 0.026).

CONCLUSIONS:

In patients with a light microscopy pattern of MCD, CD44-positive staining of PECs is associated with a higher prevalence of steroid resistance and worse kidney outcomes, and can be considered an early sign of FSGS.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Idioma: En Revista: Clin Kidney J Año: 2022 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Idioma: En Revista: Clin Kidney J Año: 2022 Tipo del documento: Article País de afiliación: España